| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Tungs’ Taichung Metroharbour Hospital |
| Information provided by: | Tungs’ Taichung Metroharbour Hospital |
| ClinicalTrials.gov Identifier: | NCT00431249 |
Purpose
Peripheral arterial disease (PAD) is the most common manifestation of systemic atherosclerosis and accounts for significant morbidity and mortality among end-stage renal disease (ESRD) patients. However, few studies have identified the prevalence and clinical impact of PAD in this specific population.
Objectives: To perform a single-blinded parallel, controlled trial to examine the effect of cilostazol treatment on plasma VEGF levels, tissue factors , inflammatory markers (such as IL-6, hsCRP) levels, oxidative stress markers in ESRD patients with PAD Material and methods Fourty HD patients on maintenance HD for > 3months were enrolled in this prospective, single-blinded, randomized study. These patients were randomly allocated into 2 arms. After baseline assessment, patients in the treatment arm received 12 weeks of added on therapy with cilostazol 100mg/day. Blood pressure, heart rate, oxidative stress (malonyldialdehyde, protein carbonyl and ADMA), inflammatory markers (hsCRP, IL-6) and plasma, VEGF and tissue factors levels were measured before and after treatment.
| Condition | Intervention | Phase |
|
Hemodialysis Patients Peripheral Vascular Disease |
Drug: Cilostazol |
Phase IV |
| MedlinePlus related topics: | Dialysis Kidney Failure Peripheral Arterial Disease Stress Vascular Diseases |
| Drug Information available for: | Cilostazol |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Single Blind, Active Control, Parallel Assignment |
| Official Title: | Effects of Cilostazol on Vascular Endothelial Growth Factor , Inflammatory and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease. |
| Estimated Enrollment: | 70 |
| Study Start Date: | February 2007 |
| Study Completion Date: | April 2008 |
 |
Show Detailed Description |
Eligibility
| Ages Eligible for Study: | 30 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations More Information
| Study ID Numbers: | 960126 |
| First Received: | February 2, 2007 |
| Last Updated: | April 4, 2008 |
| ClinicalTrials.gov Identifier: | NCT00431249 |
| Health Authority: | Taiwan: Department of Health |
|
|
|
|
